Motley Fool
Why Shares of Amarin Corporation Dropped 46.1% in May
Amarin Corporation (NASDAQ: AMRN), a biopharmaceutical company that specializes in cardiovascular therapies, saw its shares plummet 46.1% in May, according to data from S&P Global Market Intelligence. The company has only one marketed therapy, Vascepa (icosapent ethyl), which is designed to reduce the risk of stroke or heart attack by lowering harmful triglycerides, a type of fat in your blood. The problem for Amarin is that Vascepa now has three generic competitors compared to only one at this time last year.
